209 related articles for article (PubMed ID: 32228243)
21. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
Clemens KJ; McGregor IS; Hunt GE; Cornish JL
Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
[TBL] [Abstract][Full Text] [Related]
22. MDMA ("ecstasy") abuse as an example of dopamine neuroplasticity.
Schenk S
Neurosci Biobehav Rev; 2011 Apr; 35(5):1203-18. PubMed ID: 21184779
[TBL] [Abstract][Full Text] [Related]
23. Evidence for significant polydrug use among ecstasy-using college students.
Wish ED; Fitzelle DB; O'Grady KE; Hsu MH; Arria AM
J Am Coll Health; 2006; 55(2):99-104. PubMed ID: 17017306
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats.
Young JM; McGregor IS; Mallet PE
Neuropsychopharmacology; 2005 Aug; 30(8):1475-82. PubMed ID: 16178074
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying the hepatotoxic effects of ecstasy.
Carvalho M; Pontes H; Remião F; Bastos ML; Carvalho F
Curr Pharm Biotechnol; 2010 Aug; 11(5):476-95. PubMed ID: 20420570
[TBL] [Abstract][Full Text] [Related]
26. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
27. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves.
Parrott AC
Neuropsychobiology; 2004; 50(4):329-35. PubMed ID: 15539865
[TBL] [Abstract][Full Text] [Related]
28. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat.
Connor TJ; McNamara MG; Finn D; Currid A; O'Malley M; Redmond AM; Kelly JP; Leonard BE
Immunopharmacology; 1998 Jan; 38(3):253-60. PubMed ID: 9506825
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D
Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164
[TBL] [Abstract][Full Text] [Related]
30. Memory deficits associated with recreational use of "ecstasy" (MDMA).
Morgan MJ
Psychopharmacology (Berl); 1999 Jan; 141(1):30-6. PubMed ID: 9952062
[TBL] [Abstract][Full Text] [Related]
31. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.
Singer LT; Moore DG; Fulton S; Goodwin J; Turner JJ; Min MO; Parrott AC
Neurotoxicol Teratol; 2012; 34(3):303-10. PubMed ID: 22387807
[TBL] [Abstract][Full Text] [Related]
32. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
Daumann J; Hensen G; Thimm B; Rezk M; Till B; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2004 May; 173(3-4):398-404. PubMed ID: 14722704
[TBL] [Abstract][Full Text] [Related]
33. Morphological effects in the mouse myocardium after methylenedioxymethamphetamine administration combined with loud noise exposure.
Gesi M; Lenzi P; Soldani P; Ferrucci M; Giusiani A; Fornai F; Paparelli A
Anat Rec; 2002 May; 267(1):37-46. PubMed ID: 11984790
[TBL] [Abstract][Full Text] [Related]
34. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
35. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.
Parrott AC; Milani RM; Gouzoulis-Mayfrank E; Daumann J
J Neural Transm (Vienna); 2007; 114(8):959-68. PubMed ID: 17520319
[TBL] [Abstract][Full Text] [Related]
36. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
McCann UD; Eligulashvili V; Ricaurte GA
Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
[TBL] [Abstract][Full Text] [Related]
37. Modulatory effects of low-dose MDMA on cocaine-induced locomotor activity and place conditioning in rats.
Panos JJ; Baker LE
Pharmacol Biochem Behav; 2012 Jan; 100(3):377-81. PubMed ID: 21978942
[TBL] [Abstract][Full Text] [Related]
38. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.
Dafters RI; Hoshi R; Talbot AC
Psychopharmacology (Berl); 2004 May; 173(3-4):405-10. PubMed ID: 12955295
[TBL] [Abstract][Full Text] [Related]
39. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
40. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature.
Carvalho M; Carvalho F; Remião F; de Lourdes Pereira M; Pires-das-Neves R; de Lourdes Bastos M
Arch Toxicol; 2002 Apr; 76(3):166-72. PubMed ID: 11967622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
